|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Eli_Lilly_and_Company
2019
$8 billion
|
|
gptkbp:businessModel
|
biopharma
|
|
gptkbp:clinicalTrials
|
global
ongoing
Phase 1
extensive
Phase 2
Phase 3
robust
precision medicine
promising
focused
leading
Phase 1/2
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:community
|
significant
|
|
gptkbp:communityEngagement
|
active
|
|
gptkbp:communityPartnerships
|
collaborative
|
|
gptkbp:drugInterdiction
|
innovative
FDA_approved
|
|
gptkbp:employeeCount
|
approximately 100
|
|
gptkbp:environmentalConcerns
|
ongoing
|
|
gptkbp:focus
|
targeted cancer therapies
|
|
gptkbp:founded
|
2013
|
|
gptkbp:founder
|
Josh_Bilenker
|
|
gptkbp:globalPresence
|
expanding
|
|
gptkbp:hasPopulation
|
diverse
|
|
gptkbp:hasPrograms
|
experts in oncology
|
|
gptkbp:headCoach
|
rapid
|
|
gptkbp:headquarters
|
gptkb:Boulder,_Colorado
|
|
gptkbp:healthcare
|
patient-centric
|
|
gptkbp:historicalResearch
|
biotech companies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Loxo Oncology
|
|
gptkbp:investmentFocus
|
active
Venture capital firms
institutional
|
|
gptkbp:leadership
|
Josh_Bilenker,_CEO
|
|
gptkbp:leads
|
gptkb:larotrectinib
selpercatinib
|
|
gptkbp:market
|
publicly traded
rare cancers
|
|
gptkbp:marketingStrategy
|
growth-oriented
|
|
gptkbp:marketSegment
|
innovative
|
|
gptkbp:notableFeature
|
LOXO-292
Vitrakvi
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
pharmaceutical companies
|
|
gptkbp:patentCitation
|
numerous
|
|
gptkbp:patentType
|
2018
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
|
|
gptkbp:research
|
significant
|
|
gptkbp:research_areas
|
oncology
multiple cancer types
|
|
gptkbp:researchAndDevelopment
|
high investment
|
|
gptkbp:researchFocus
|
genetic drivers of cancer
|
|
gptkbp:researchInterest
|
numerous
|
|
gptkbp:scientificName
|
core value
|
|
gptkbp:stockSymbol
|
LOXO
|
|
gptkbp:technology
|
genomic profiling
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:tributaryOf
|
multiple drug candidates
|
|
gptkbp:website
|
www.loxooncology.com
|